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Summary
 
Quantitative analysis of the relationship between virus expression and disease outcome has
been critical for understanding HIV-1 pathogenesis. Yet the amount of viral RNA contained
within an HIV-expressing cell and the relationship between the number of virus-producing
cells and plasma virus load has not been established or reflected in models of viral dynamics.
We report here a novel strategy for the coordinated analysis of virus expression in lymph node
specimens. The results obtained for patients with a broad range of plasma viral loads before and
 
after antiretroviral therapy reveal a constant mean viral (v)RNA copy number (3.6 log
 
10
 
 copies)
per infected cell, regardless of plasma virus load or treatment status. In addition, there was a sig-
 
nificant but nonlinear direct correlation between the frequency of vRNA
 
1
 
 lymph node cells
and plasma vRNA. As predicted from this relationship, residual cells expressing this same mean
 
copy number are detectable (frequency 
 
,
 
2/10
 
6
 
 cells) in tissues of treated patients who have
plasma vRNA levels below the current detectable threshold (
 
,
 
50 copies/ml). These data sug-
gest that fully replication-active cells are responsible for sustaining viremia after initiation of
potent antiretroviral therapy and that plasma virus titers correlate, albeit in a nonlinear fashion,
with the number of virus-expressing cells in lymphoid tissue.
Key words: HIV-1 infection • quantitative RT-PCR • lymph node biopsy • in situ 
hybridization • HIV pathogenesis
 
T
 
he amount of HIV-1 in blood correlates with the risk of
clinical progression to AIDS (1, 2) and provides a useful
assay to evaluate responses to antiretroviral therapy (3, 4).
However, a large proportion of the virus in the body (as
 
measured by detection of viral [v]RNA)
 
1
 
 is present in lym-
phoid tissues (5). There is limited and conflicting quantita-
tive information available regarding the correlation between
tissue and blood HIV-1 pools, the extent and distribution of
residual HIV-infected cells in tissue compartments after the
extensive reduction in plasma HIV RNA associated with ef-
fective therapy, and the quantitative relationship between
the number of virus-expressing cells and plasma virus load
(5–9). A critical component in formulating an accurate and
comprehensive model of HIV pathogenesis based on these
parameters is the analytical distinction between vRNA in-
side infected cells and the extracellular virions trapped in
the follicular dendritic cell (FDC) network of lymph node
germinal centers (6, 7). Although lymphoid tissue contains
much more vRNA than blood, the technical challenges of
quantitative analysis are compounded by the relative diffi-
culty of obtaining adequate lymphoid tissue and the inher-
ent complexity of tissue compared with blood plasma. To
address these issues, and because the quantitative assessment
of different viral compartments in vivo is crucial to under-
standing the complex dynamic relationships between cellular
populations and different forms of viral genetic material, we
 
have developed an alternative strategy to measure the amount
of vRNA within tissue compartments. Three sets of analyses
were performed on the same fresh-frozen tissue specimen: a
sensitive in situ hybridization (ISH) procedure (10, 11); quan-
titative, competitive RT-PCR (QC-RT-PCR) analysis of
the bulk tissue; and QC-RT-PCR analysis of individual cells
isolated from tissue at limiting dilution.
 
1
 
Abbreviations used in this paper: 
 
FDC, follicular dendritic cell; HAART,
highly active antiretroviral therapy; ISH, in situ hybridization;
 
 
 
LDA, lim-
 
iting dilution analysis; QC-RT-PCR, quantitative, competitive RT-PCR;
 
UTP, uridine 5
 
9
 
-triphosphate; vRNA, viral RNA. 
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Materials and Methods
 
Lymph Node Tissue Processing.
 
After appropriate informed con-
sent, subjects underwent an excisional lymph node biopsy under
local anesthesia in an outpatient operating room. The tissue was
obtained from levels 3 and 4 of the posterior cervical chain, with
the second biopsy obtained from the contralateral site. In each
case, the largest palpable lymph node was selected for excision.
The freshly excised lymph node tissue was immediately cut into
pieces, and a measured portion was snap frozen under OCT
compound as a block of tissue; the remaining portion was sepa-
rated into a single-cell suspension by mechanical disaggregation.
The single-cell suspension was counted and used for several dif-
ferent analyses, including the preparation of microtiter wells used
for a limiting dilution analysis (LDA) of vRNA-expressing cells.
 
Production of Probes for ISH.
 
Probes for ISH of HIV-1 RNA
were produced from three separate plasmids (covering sequences
225–3378, 5546–7308, and 7308–9107; sequence data available
from EMBL/GenBank/DDBJ under accession no. L02317) that
were linearized, and single-stranded RNA molecules were pro-
duced by in vitro transcription. During the transcription, digoxi-
genin-UTP ([uridine 5
 
9
 
-triphosphate]; Boehringer Mannheim)
or 
 
35
 
S-UTP was directly incorporated into the sequence as de-
scribed (12). For the digoxigenin-labeled probes, three separate
antisense probes were made, quantified by trace labeling with 
 
3
 
H
during transcription, and hydrolyzed for 10 min in 20 mM
NaHCO
 
3
 
, pH 10.2, to yield labeled fragments of 
 
z
 
300 bp. The
three probe preparations were then mixed at equal molar
amounts and used at 0.1 fm/
 
m
 
l in hybridization buffer for ISH.
The procedure was performed as previously reported (11–13).
The color reaction was stopped by rinsing the slides in Tris-
EDTA buffer, pH 8.0, and the sections mounted in aquamount.
 
Quantitative Morphometric Analysis.
 
The frequency of HIV
RNA
 
1
 
 cells was counted by direct microscopic observation, using
a calibrated ocular grid, by an observer blinded to the other anal-
yses performed on the same specimen. The frequency of individ-
ual vRNA
 
1
 
 cells was counted in multiple adjacent sections, and
the total area occupied by lymphoid tissue and density of cells
was determined in each section. In each case, the number of HIV
RNA
 
1
 
 cells and the total lymphoid tissue area was determined
for each section. The number of adjacent sections analyzed de-
pended on the frequency of positive cells and ranged from 5 to
100 sections per lymph node. The density of cells was deter-
mined by counting nuclei in an adjacent hematoxylin and eosin–
stained section for each case. Among these specimens, the mean
number of cells (nuclei)/mm
 
2
 
 was 12,500. By comparing the
number of positive cells with the total amount of lymphoid tissue
examined, the frequency of positive cells per 10
 
6
 
 total cells was
calculated. ISH analysis of lymph node tissue from HIV
 
2
 
 individ-
uals, using riboprobes with the same HIV-1 sequences in sense
orientation or probes specific for murine sequences, failed to
identify any positively stained cells (data not shown).
 
QC-RT-PCR.
 
HIV RNA was quantitated by a modification
of the procedure described previously (14). The synthetic com-
petitor for HIV analysis was constructed by ligation of the 5
 
9
 
 and
3
 
9
 
 respective oligonucleotide templates into the general cloning
vector pQPCR1 as described (14). This pQPCR.HRV2 com-
petitor contained several primer sets, one of which was a site in
the HIV-1 
 
pol
 
 gene designed to amplify a 415-bp fragment ex-
tending from position 2713 to 3127 in the HIV genome (based
on the position number available from EMBL/GenBank/DDBJ
under accession no. K03455). All competitors were used to gen-
erate single-stranded competitor RNA molecules, which were
purified based on a specific hybridization tag 3
 
9
 
 to the reverse
 
primer cassette and quantitated by trace labeling with a known
specific activity of 
 
3
 
H-UTP.
The single tube quantitative PCR technique, a modification of
the multi-tube quantitative PCR technique (14), was performed
by adding GITC extract containing an unknown amount of
HIV-1 RNA to a competitor cocktail containing five different
synthetic HIV competitors at a series of concentrations differing
by 0.4 log
 
10 
 
multiples. For example, competitor cocktail 3 con-
sists of competitor A at log
 
10
 
 3 (1,000 copies), competitor B at
log
 
10
 
 3.4 (2,510 copies), etc. Each competitor differed from the
others by an internal 25-bp segment of DNA that is the basis for
differential hybridization and detection. Extraction, cDNA gen-
eration, and quantitative PCR were performed as described (14).
The enzyme immunoassay detection procedure was also carried
out essentially as described (14), except that each PCR product
was plated into 12 microtiter wells instead of 4. Two wells each
were probed with detection oligonucleotides for the HIV-1 gene
and stuffer detection oligos specific for competitors A, B, C, D,
and E. Calculation of endpoints was performed as described (14).
The 
 
pol
 
 gene primers used were: upstream oligo, 5
 
9
 
-CATA-
CAATACTCCAGTATTTGCCA; and 
 
pol
 
 downstream oligo,
5
 
9
 
-AAGTCAGATCCTACATACAAATCA. PCR conditions for
 
pol
 
 amplification were: 0.8 
 
m
 
M primers, 2.6 mM Mg
 
2
 
1
 
, and
50
 
8
 
C annealing for 35 cycles. The detection oligonucleotide for
hybridization of the internal HIV sequence was 5
 
9
 
-TGGATGT-
GGGTGATGCATATTTTTCAGTTC; each different competi-
tor species was detected with a distinct 25-mer sequence using
standard hybridization conditions (14).
For determination of the bulk amount of vRNA in tissue, 20–40
4-
 
m
 
m sections were cut from the frozen tissue block adjacent to
other sections used to perform ISH and immunohistochemical
analysis. This material was immediately solubilized by adding 10 
 
m
 
l
GITC/section to a tube containing the frozen sections and was
used for the QC-RT-PCR analysis as described above (termed
tissue homogenate).
 
LDA.
 
A measured portion of each lymph node biopsy speci-
men was separated in the operating suite and transported imme-
diately to the containment lab in ice cold balanced salt solution.
The tissue was separated into a single-cell suspension by standard
mechanical disaggregation techniques, washed, and counted.
Limiting diluted wells were prepared by dispensing 500, 1,000,
5,000, or 10,000 cells into 36 replicate microtiter wells in 10 
 
m
 
l
HBSS with 10% FCS, and then 100 
 
m
 
l GITC was added to each
well. Individual wells were analyzed by QC-RT-PCR as de-
scribed using a competitor cocktail with the lowest individual
competitor concentration at 1,000 copies/reaction. The loga-
rithm of the fraction of negative wells (
 
,
 
1,000 vRNA) was plot-
ted against the number of cells per well. Regression lines passing
through the origin were calculated and used to estimate the pre-
cursor frequency of positive cells. When the frequency of nega-
tive wells is 
 
.
 
40%, most of the positive wells contain only a sin-
gle positive cell and, therefore, the copy number directly
determined by the QC-RT-PCR procedure in those positive
wells is also a direct measure of the copy number per replication-
active cell in vivo.
 
Results
 
Patient Characteristics.
 
The analysis contained herein was
applied to cervical lymph node biopsy specimens obtained
from nine patients with a wide spectrum of plasma HIV 
1547
 
Hockett et al.
 
RNA levels, six of whom had serial biopsies performed
before and after the introduction of highly active antiretro-
viral therapy (combinations of HIV-1 protease inhibitors
and two reverse transcriptase inhibitors). All of the subjects
were in relatively advanced stages of HIV disease, with
 
,
 
350 CD4 T cells/
 
m
 
l. The plasma vRNA levels and the
absolute blood CD4 cell counts concurrent with the biop-
sies, the timing of the biopsies relative to therapy, the spe-
cific antiretroviral regimens involved, and the quantitative
results obtained in this analysis are shown in Table I.
 
Validation of the QC-RT-PCR Technique.
 
Fundamental to
these studies was the development of a procedure to accu-
rately quantify the HIV vRNA from tissue specimens. Us-
ing primers specific to various regions of the HIV genome
detecting only full length, unspliced message (see Materials
and Methods), a modification of the previously described
 
QC-RT-PCR assay was employed (14). To verify the ac-
curacy of our QC-RT-PCR assay, we compared this assay
to two other independent methods for HIV RNA quanti-
tation, using a series of plasma specimens obtained from
patients in various clinical stages of HIV infection as well as
a standard HIV RNA preparation obtained from the
National Institutes of Health AIDS reagent repository. The
results of this analysis (Fig. 1) demonstrated excellent con-
cordance between the UAB QC-RT-PCR and the Roche
Amplicor HIV Monitor
 
®
 
 assay (15), whereas comparison
with the branched chain DNA (bDNA; Chiron) assay (16)
using the same specimens revealed the previously described
slight systematic bias toward lower viral load results in the
bDNA assay (data not shown). Thus, the independently
constructed QC-RT-PCR assay provides results equivalent
to the Roche assay over a wide range of RNA concentra-
 
Table I.
 
Comparison of Three Independent Methods of Analysis of HIV RNA in Lymph Node Tissue
 
Summary of quantitative analysis of HIV vRNA in a series of patients undergoing excisional lymph node biopsies. Subjects are identified by a four-
letter code, and information concerning drug treatment at the time of the biopsy, the time after the change in therapy before the second (or third)
biopsy, the plasma viral load, and CD4 T cell count determined on a blood specimen obtained the same day the biopsy is given. Results obtained
from the ISH analysis of tissue sections are shown as a histologic score (Neg to 4
 
1
 
) for germinal center–associated vRNA signal, and the frequency
of individual vRNA positive cells expressed per million lymph node cells examined. Results from LDA (see Fig. 3) are given as frequency of cells
scored positive by QC-RT-PCR (Fig. 3 A) and mean (
 
6
 
SEM) of absolute copies measured in each positive well at limiting dilution (Fig. 3 B). The
right-most column shows the results of analysis of a series of adjacent frozen sections obtained from the face of the tissue block used for ISH analysis
that were analyzed for the bulk amount of vRNA by QC-RT-PCR. The measured amount of vRNA in this extract is expressed per million cells
homogenized, which was calculated using the measured area (mm
 
2
 
) of each section, the density of cells/mm
 
2
 
, the thickness of the section (4 
 
m
 
m),
and an estimate of 12 
 
m
 
m for the average diameter of a lymphocyte. Thus, the denominators for both the bulk tissue amount of vRNA by QC-RT-
PCR and the frequency of vRNA
 
1
 
 cells by ISH are the same, such that the simple ratio of these measurements yields an estimate of the vRNA cop-
ies per positive cell that is completely independent of the result obtained from the LDA. For the average copy number per cell by bulk analysis, only
those samples that were scored as negative for FDC-associated virus were included. The determination of copy number per cell by the two methods
was not significantly different using the Mann–Whitney Rank sum test or Student’s 
 
t
 
 test, comparing either the cases with or without significant
FDC signal, respectively. In those cases in which there was significant FDC-associated vRNA detected by ISH, this bulk tissue estimate of vRNA
copies per cell is higher than either the LDA determined estimate or the bulk tissue estimate on those specimens without FDC vRNA signal.
 
*
 
not done. 
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tions. By using dilutions of specimens containing varying
concentrations of HIV vRNA, this QC-RT-PCR (14)
assay has a sensitivity of 
 
z
 
100 copies/reaction (data not
shown).
 
Limiting Dilution QC-RT-PCR Analysis of Lymph Node
Biopsy Specimens Reveals a Constant Mean Viral RNA Copy
Number per Cell.
 
The goal of these studies is to accurately
quantitate the amount of virus contained in HIV-infected
cells and to cross-validate the results using independent
procedures. The sensitivity of RT-PCR allows single-cell
analysis; therefore, the current study began by assessing the
vRNA content of individual HIV-infected cells. To di-
rectly determine the frequency and vRNA content of
lymph node cells actively producing virus, five individual
biopsy specimens obtained before combination antiretrovi-
ral therapy were subjected to LDA. Both the frequency of
individual cells expressing detectable vRNA (Fig. 2 A) and
the copy number per cell (copies/well at limiting dilution;
Fig. 2 B) were directly determined. The mean copy num-
ber of vRNA per cell for each patient is remarkably consis-
tent (3,900 or 3.6 log
 
10
 
 copies/cell [range: 3.5–3.7 log
 
10
 
copies/cell]; Table I).
 
The Frequency of HIV vRNA–expressing Cells Is Compara-
ble by LDA and ISH.
 
To corroborate the QC-RT-PCR
data, the frequency of vRNA
 
1
 
 cells was also determined by
ISH analysis using digoxigenin-labeled riboprobes as previ-
ously described (10, 11). As observed by others using
 
35
 
S-labeled riboprobes (5, 6, 17–19), HIV RNA is present
in lymphoid tissue in two distinct patterns: within individ-
Figure 1. Plasma samples from HIV-infected patients were obtained
and immediately separated into 1-ml aliquots, which were analyzed by
each of two methods with blinded results. In addition, a standard prepara-
tion of HIV RNA was obtained from the National Institute of Allergy
and Infectious Diseases AIDS Research and Reference Reagent Program
and analyzed by the UAB QC-RT-PCR procedure. Roche Monitor®
assay was performed as per manufacturer’s instructions. Specimens with
viral loads .5 3 105/ml were analyzed after appropriate dilution. The
UAB QC-RT-PCR procedure was performed as described in Materials
and Methods.
Figure 2. Analysis of HIV RNA1 cells by LDA and single-cell UAB
QC-RT-PCR. (A) LDA for the frequency of HIV vRNA–expressing cells
on five untreated patients described in Table I. After dilution of lymph node
cells in 96-well microtiter plates, each well was harvested and QC-RT-PCR
performed. For the graph in A, wells were scored positive or negative for
HIV vRNA only. The number of lymph node cells diluted per well is plot-
ted along the x-axis, and the percent negative wells by QC-RT-PCR is
plotted along the y-axis. The frequency of HIV vRNA–expressing cells per
106 lymph node cells was calculated by Poisson statistics. (B) Frequency his-
tograms for four of the LDAs graphed in A for quantification of copies per
well. The range of copies per well for each bar on the x-axis represents 0.3
log10 multiples of copies of HIV vRNA. Only positive wells (.1,000 cop-
ies) were used for the calculation of mean HIV vRNA copies per well. See
Table I for summary of other patient data and calculations of HIV vRNA
quantity in different pools. 
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ual cells (Fig. 3, A and B) and between cells in the FDC
network of germinal centers (Fig. 3, C and D). The fre-
quency of vRNA
 
1
 
 cells we observed by ISH is comparable
to the frequency of vRNA
 
1
 
 cells determined by the inde-
pendently performed LDA method on adjacent portions of
the same tissue specimen (Table I). In this series of patients,
most with relatively advanced HIV disease, many of the
lymph nodes demonstrated negligible amounts of ISH sig-
nal associated with germinal centers. Nevertheless, in each
specimen, morphological germinal centers were identified
by immunohistochemistry (data not shown). In several
cases, the ISH procedure was repeated with 
 
35
 
S-labeled
HIV riboprobes and with proteinase K–digested tissue as
described (6, 17), with results equivalent to those of digox-
igenin-labeled probes for both frequency of individual
vRNA
 
1
 
 cells and detection of FDC virions (data not shown).
The relative intensity and extent of germinal center–associ-
ated virus was assessed on a semiquantitative visual scale
(Table I), but no attempt to precisely calculate numbers of
vRNA molecules was made based on this image analysis.
Although several of these tissue specimens from advanced
HIV disease patients (CD4 
 
,
 
200 cells/
 
m
 
l) had negligible
FDC-associated vRNA signal, in this analysis the quantifi-
cation of vRNA was carried out exclusively using the stan-
dardized soluble vRNA assay by QC-RT-PCR.
 
The HIV RNA Mean Copy Number per Cell Is Similar be-
tween LDA and Bulk Tissue Analysis When FDC-associated
Virus Is Minimal.
 
To cross-validate the HIV RNA mean
copy number per cell by LDA, a further independent anal-
ysis of the vRNA content of homogenized tissue was per-
formed on each biopsy specimen. Tissue homogenates
from serial sections from the same tissue block used for the
ISH analysis were made as described. The amount of vRNA
present in tissue homogenates, representing both individual
vRNA-expressing infected cells and free virions trapped in
FDC structures, was then directly determined using the
QC-RT-PCR procedure and is expressed in Table I as
HIV RNA copies/million lymph node cells (see 
 
Bulk Tis-
sue Analysis
 
). The total amount of tissue vRNA was then
divided by the number of HIV-expressing cells detected by
ISH and the results listed as HIV RNA Copies/Cell bulk/
ISH in Table I. Consistent with the LDA data, when FDC-
associated virus was not detected (Neg), the HIV RNA
Copies/ISH
 
1 cell hovered around 5,000 copies. When sig-
nificant FDC-associated virus was detected by ISH, then
the HIV RNA copies/ISH1 cell was much higher (Table I;
see patients BABI, EVJE, and TRRA). Thus, the detection
of FDC-associated virions is not simply dependent on the
sensitivity of the ISH analysis. Direct measurement of total
tissue vRNA detects significantly more vRNA than can be
Figure 3. Representative photomicrographs of ISH for HIV RNA. (A) Suspension of normal PBMC infected with HIV-1 in vitro. (B) HIV RNA1
cell identified in lymph node frozen tissue section. (C) Lymph node section of patient HADE showing HIV RNA in germinal center of lymph node
scored as 11 and two individual positive single cells. (D) Lymph node section of patient TRRA showing HIV RNA in germinal center of lymph node
scored as 31 and two individual positive single cells.1550 Constant HIV Mean Viral Copy Number
accounted for by the frequency of individual vRNA1 cells
only in those cases where FDC signal is detected by quali-
tative ISH methodology.
The Frequency of HIV vRNA–expressing Cells Is Related to
the Plasma Viral Load. The relatively constant mean vRNA
content per cell implies a constant instantaneous produc-
tion of HIV virions (instantaneous burst size). Although the
actual burst size represents the total virus production over
the lifetime of the cell and depends upon several factors
(see below), one prediction of a constant burst size would
be a direct correlation between the number of infected cells
and the plasma viral load over a broad range of values. To
investigate this possibility, we compared the frequency of
vRNA1 cells per million lymph node cells determined by
ISH with the plasma viral load of the patient at the time of
the biopsy (Fig. 4). As predicted, there was a direct and
highly significant correlation between the logarithm of the
vRNA1 cell frequency in lymph node tissue and the loga-
rithm of the plasma vRNA. The slope of this relationship is
relatively constant, whether the data derives from different
patients (slope 5 1.6; Pearson product moment correlation
coefficient (r) 5 0.89; P , 0.0005) with widely varying vi-
ral loads (a 6 log10 range) before protease inhibitor therapy
or from patients undergoing serial biopsies before and after
potent therapy (Fig. 4, mean of individual slopes 5 1.6;
points connected by lines). The overall relationship among
the logarithms of these values is highly significant (slope 5
1.6; r 5 0.95; P , 1028). Although the relationship is con-
sistent over a wide range of viral load values, the direct cor-
relation is not 1:1 (that is, the slope of the log–log plot ¹ 1).
This result differs from predictions based on standard math-
ematical models of viral dynamics (20, 21). In other words,
a 1 log10 drop in the number of vRNA1 cells in lymph
node tissue is associated with a 1.6 log10 drop in vRNA in
plasma. The interpretation of this observation remains open
for speculation, but the consistency of this direct relation-
ship over such a broad range of viral load values is a novel
observation that must be accounted for in quantitative
models of viral dynamics.
Persistence of vRNA-expressing Cells in Lymph Node Tissue
Despite Undetectable Plasma Viral Load. In each of the three
biopsy specimens obtained from subjects on stable highly
active antiretroviral therapy (HAART) with a plasma viral
value ,50 copies/ml, we continued to detect individual
vRNA1 cells by ISH, albeit at extremely low frequency.
This analysis required examination of 50–100 sections
spaced at least 12 mm apart to detect the few positive cells.
The quantification of the total vRNA from the inter-
spersed sections used for ISH analysis divided by the fre-
quency of vRNA1 cells detected by ISH indicated a copy
number per cell similar to that obtained during episodes of
high viral replication (Table I). Although this estimate is
not highly precise due to the low number of total cells de-
tected, these data indicate that the majority of detectable
vRNA molecules in lymph node tissue of subjects on
HAART is contained within a few individual cells. Because
the copy number estimate for these residual cells is similar
to that measured by both LDA and bulk tissue analysis in
subjects not treated with antiretroviral drugs, it is likely that
these very few cells represent fully replication-active cells,
rather than some form of abortive transcriptional activity.
Discussion
This coordinated analysis of HIV vRNA by three inter-
locking but independent methods (ISH, QC-RT-PCR of
bulk tissue, and LDA) provides cross-validation of the re-
sults. First, we found that the frequency of positive cells de-
termined by ISH is equivalent to the frequency determined
independently by LDA (Table I). Thus, the sensitivity of
ISH for detecting individual vRNA1 cells was directly val-
idated by the completely independent method of LDA,
which has not been performed when using other ISH
methods. Second, when there was negligible FDC-associ-
ated virus detected by ISH, the copy number of HIV RNA
per cell determined by LDA is equivalent to the vRNA
copies present in bulk tissue divided by the frequency of
cells. In contrast, when significant FDC-associated vRNA
was detected by ISH, this ratio was higher than the inde-
pendent estimate of copy number determined by LDA
(Table I). These data imply that the ISH procedure using
digoxigenin-labeled riboprobes is not missing significant
amounts of FDC-associated virus when it is present. If ISH
was underestimating the extent of FDC-associated virus,
then the copy number calculated based on the bulk tissue
method would not match the result obtained by LDA. As
the quantification of vRNA copies is not performed by im-
age analysis of the ISH signal but rather by the standardized
soluble QC-RT-PCR assay, this quantification does not
directly depend on the sensitivity of detection by ISH.
Even if the intensity of the FDC-associated ISH signal is
weaker using this ISH procedure, this potential problem
does not affect the analysis based on cross-validation of in-
Figure 4. Relationship of plasma viral load to HIV vRNA–expressing
cells in lymph node tissue. Each point represents a separate biopsy speci-
men paired with the plasma viral load at time of biopsy. HIV vRNA1
cells were measured by ISH, and plasma viral loads were determined by
the Roche Monitor® ultra-sensitive assay. The lines connecting points
with the same symbols represent the same patient before and after
HAART, as shown in Table I. Overall regression line (using the log-
transformed data) of these data: slope 5 1.6; r 5 0.95 (P , 1028).1551 Hockett et al.
dependent methods. For example, the first biopsy of a sub-
ject with advanced disease (Modified Card Sorting Test
[MCST], CD4 count 5 27; viral load 5 1.1 3 106; Table I)
showed negligible FDC signal. The frequency of individual
positive cells was essentially equivalent by two independent
methods (140/106 cells by ISH and 125/106 cells by LDA).
The copy number per positive cell was also equivalent by
two independent methods (3,700 copies/cell by LDA and
4,100 copies/cell by the ratio of total tissue RNA divided
by the frequency of identified cells). If there was significant
FDC virus in this tissue specimen, then this cross-validation
would not have been observed. Indeed, when significant
qualitative FDC signal was observed, there was significantly
more total vRNA in tissue than could be accounted for by
the frequency of individual positive cells (Table I; see sub-
jects BABI, EVJE, and TRRA before HAART). Thus, this
analysis is internally validated by independent methods,
with the quantitation depending on the QC-RT-PCR
analysis of soluble RNA rather than image analysis. The
measurement of soluble RNA has been standardized using
both internal and external standards and is comparable to
the Roche Amplicor HIV Monitor® assay (15) (Fig. 1).
This analytical approach demonstrates that each vRNA-
expressing cell in patient lymph node tissue contains, on
average, z3.6 log10 (or z4000) copies of HIV RNA. This
result is independent of the frequency of infected cells, the
plasma viral load or CD4 count, or the form or potency of
the antiretroviral being administered at the time of the biopsy.
Our determination of the HIV RNA copies per cell is
significantly higher than that of previous results based on
image analysis using 35S-labeled probes (17, 18, 22, 23).
Furthermore, in a recent report, image analysis of lymph
node specimens from patients with acute and early HIV in-
fection did not demonstrate a relationship between infected
cell frequency in tissue and plasma viral load (24). Although
previous investigators have emphasized the major predomi-
nance of FDC-associated virions over intracellular virus, in
the current analysis the degree of trapping of virions in
lymph node germinal centers is less than previously reported
(17, 22). It is likely that this discrepancy in absolute quanti-
fication of copies per detectable vRNA1 cell is due to
the standardization of the method used to determine copy
number. Molar quantification using image analysis of
35S-based ISH relies on complete efficiency of RNA pres-
ervation and probe access in fixed, paraffin-embedded
tissue and 100% efficiency of grain production in the emul-
sion. These assumptions have not be independently vali-
dated. In separate experiments not reported here, both of
these potential problems appear to be significant. To exam-
ine the efficiency of grain production in the emulsion for
35S-labeled probe ISH, we measured the frequency of in-
fected cells and counted grains over each positive cell in
populations of HIV-1 infected PBMC. Calculation of copy
number by grain count, using the specific activity of the
probe and time of emulsion exposure as described (17),
generated a significantly lower estimate of copy number
per cell than direct QC-RT-PCR analysis of 10,000 such
cells (corrected for the fraction that was vRNA1). By this
analytical approach, detection of silver grains is only about
5% efficient; in other words, determination of the probe
specific activity in a well scintillation counter is more effi-
cient than silver grain production in a very thin emulsion.
To examine the potential loss of signal by tissue block
fixation and paraffin embedding, the expression of murine
Ig m heavy chain mRNA was compared in fresh-frozen tis-
sue versus formalin-fixed, paraffin-embedded tissue. Both
small B cells in primary follicles and sinusoidal plasma cells
were detected by digoxigenin-labeled riboprobes in frozen
tissue, whereas only the plasma cells were clearly detected
in formalin-fixed, paraffin-embedded tissue. Thus, previous
reports that used the image analysis method of RNA quan-
titation may have two systematic errors that lead to an un-
derestimation of the amount of cell-associated virus.
Another aspect of the precision and sensitivity of ISH
analysis is the discrimination of cells with positive ISH sig-
nal from cellular debris that nonspecifically binds the labeled
riboprobe. Although debris of irregular shape and size larger
than a cell can be discriminated with both techniques, the
immunoenzymatic signal is detected directly in the same
focal plane as the individual cell in thin section, unlike de-
tection of grains deposited in a photographic emulsion
above the tissue section. This additional criterion of mor-
phological analysis allows discounting of rare bits of debris
that are similar in size and shape to individual cells but lo-
calized out of the plane of section using the digoxigenin
system. Perhaps previous reports of significant decreases in
the grain count per cell with therapy (17) may be due to
inclusion of a higher fraction of artifactual localized accu-
mulations of grains with lower grain density in the setting
of a very low absolute frequency of HIV positive cells.
Although interpretation of the relative sensitivity of vari-
ous histochemical techniques is controversial and has not
been cross-validated by multiple independent laboratories,
the analysis presented in this report is not fundamentally
dependent upon the quantitative sensitivity of the ISH pro-
cedure. Rather than simply assume that the frequency of
cells detected by ISH was correct, we directly confirmed
this frequency by an independent LDA method. Further-
more, the paucity of FDC signal intensity in some of these
specimens was directly confirmed by analysis of a bulk
quantity of RNA in these tissues. Thus, unlike other analy-
ses of HIV RNA in tissue, this analysis depends on quanti-
tative agreement between several independent analytical
methods rather than sole reliance on ISH methodology.
In addition to the novel methodological approach, the
biological implications of the findings presented here are
significant. The invariant mean HIV RNA copy number
per cell regardless of treatment history or stage of disease
implies that infected cells in tissue maintain a constant in-
stantaneous burst size. The actual burst size is dependant on
the life span of the replication-active cell and rate of virion
budding in addition to the cell-associated vRNA pool size.
We hypothesize that viral production at the single-cell
level may be an all-or-none phenomenon, analogous to the
situation described for T cell cytokine gene expression (10,
13, 25). The consistency of vRNA amount in productively1552 Constant HIV Mean Viral Copy Number
infected cells during treatment with antiretroviral drugs is
consistent with the mechanism of action of these agents,
which inhibit either reverse transcription or maturation of
viral particles rather than transcriptional activity. Although
the precision of the estimate of copy number per identified
vRNA1 cell in the few cases with very low cellular fre-
quency is not sufficient to rule out a modest change after
therapy, a substantial change of .10-fold as reported pre-
viously (17) is not supported by this analysis.
Independent of the measurement of absolute copies of
vRNA present in each cell, the frequency of such cells is
highly correlated with plasma viral load. The surprising ob-
servation that this relationship is nonlinear (slope of log–log
plot ¹1) requires some modification of the standard models
of viral dynamics (20, 21). One potential explanation for
this observation is that the production rate of plasma virus
is significantly modified by the presence of antiretroviral
drugs. Several lines of evidence argue against this possibil-
ity. First, the mechanism of action of these agents is a
blockade of de novo infection, either by inhibition of re-
verse transcription or extracellular maturation of virion par-
ticles rather than transcriptional inhibition or virion bud-
ding. Second, our demonstration of a roughly constant
amount of vRNA in individual cells argues that the amount
of intracellular vRNA awaiting assembly and budding is
not altered by these agents. Finally, the same nonlinear re-
lationship is found when comparing different individual
subjects before therapy but with differing viral load set
points. Thus, the nonlinear character of this relationship
cannot arise from alteration of viral production rate per cell
induced by antiretroviral therapy.
Another potential explanation is that clearance of viral
particles is a direct function of viral load. To account for
the extent of nonlinearity over the range of viral load val-
ues examined, the clearance rate must vary by z100-fold
in a consistent relationship to viral load. Although anti-
body-mediated clearance rate may be more efficient for
low virus load and may be saturated at high virus load, it
seems unlikely that such a tremendous variation in clear-
ance rate could account for these observations.
Alternatively, we favor a hypothesis that focuses on the
different in vivo tissue compartments containing replica-
tion-active cells and their relative contribution to the sys-
temic plasma viral load. It is possible that most of the in-
fected cells are present in spleen and gut rather than lymph
nodes due to the sheer volume of these compartments. As
the T cell zones in lymph nodes are single, relatively con-
tiguous areas unlike the larger spleen and gut tissue envi-
ronments, the density of infection in these areas may be
consistently higher at any given steady state level. The ef-
fect of decreased efficiency of cell-to-cell transfer of infec-
tious virus induced by antiretroviral drugs may thus have a
lesser effect on the lymph node microenvironment than on
the bulk of the lymphoid tissue present in spleen and gut. A
comprehensive, quantitative analysis of various tissue com-
partments containing infected cells in rhesus macaques in-
fected with SIV variants may provide a direct experimental
test of this model.
A clinically relevant prediction based on the observed re-
lationship between vRNA1 cell frequency and plasma viral
load is that cells actively replicating viral proteins persist af-
ter the substantial decline in plasma viremia observed dur-
ing combination antiretroviral therapy. The correlation of
plasma virus load with the frequency of vRNA1 cells over
the six log range of quantifiable viral load suggests that this
relationship is quite robust. The intercept of this relation-
ship at “undetectable” plasma viral load is z1 vRNA1
cell/million lymph node tissue cells. Given the large lym-
phoid tissue mass present in the entire body (estimated at
1011 cells), a reasonable interpretation of these data is that
z100,000 cells with viral replication potential could persist
in an infected subject, but the virions produced by these
few cells would be cleared too quickly to achieve a detect-
able steady state concentration in plasma. The extrapolation
of this relationship to plasma viral load values of ,50 cop-
ies/ml is validated by our direct observation of cells containing
full length viral transcripts within tissue specimens from three
patients with concomitant “undetectable” plasma viremia.
The origin and fate of the few residual vRNA1 cells in
patients with substantial drug-induced suppression of viral
replication is of fundamental importance for understanding
HIV disease pathogenesis and developing further therapeu-
tic alternatives for HIV-infected individuals. If these cells
represent new rounds of de novo cellular infection, the im-
plications concerning the eventual emergence of drug-
resistant mutants are significant. Alternatively, these few
cells could represent in vivo activation of latently infected
cells, a process not blocked by HAART. If the virions pro-
duced by such activated, latently infected cells do not com-
plete the viral life cycle due to effective antiretroviral ther-
apy, new mutations will not be fixed in the viral population.
The apparent extremely low clearance rate of such latently
infected cells in subjects on prolonged HAART (26–28)
may be attributable to a decreased antigen-driven immune
clearance mechanism of these cells (29) rather than a com-
plete failure of these cells to ever become transcriptionally
active. Whatever the biological origin of these few residual
vRNA1 cells, their persistence may result in rapid reigni-
tion of high level viral replication after discontinuation of
antiretroviral drugs. Consistent with such a conceptual
model are anecdotal reports that patients who discontinue
combination antiretroviral therapy, even after many months
of apparently complete viral suppression in the blood, ex-
perience a rapid return of viremia. Attempts to accurately
determine the status of HIV infection in aggressively
treated hosts must take into account both the residual pool
of latently infected cells and the presence of persistent ac-
tive viral replication in lymphoid tissue cells. Although com-
bination antiretroviral regimens can reduce plasma HIV
RNA levels below current detection limits, our data demon-
strate that this parameter is inadequate to measure the extent
to which potentially infectious virus remains in other sites
(such as lymphoid tissue). Therapeutic strategies that attempt
to completely eradicate HIV must be based on firm, quanti-
tative information concerning both blood and tissue sources
and the biological nature of residual HIV-1 virus.1553 Hockett et al.
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